Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-Prognosis Advanced Lymphoid Malignancies.

Trial Profile

Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-Prognosis Advanced Lymphoid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Rituximab
  • Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2016 Trial phase changed from phase I/II to phase I
    • 24 Sep 2012 Planned number of patients changed from 143 to 145 as reported by ClinicalTrials.gov.
    • 10 Sep 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top